Form 4: Liquidia Corp Chief Business Officer Reports Routine Stock Transactions for Tax Purposes

Liquidia Corp's Chief Business Officer, Jason Adair, reported the vesting of performance stock units and a subsequent sale of shares to cover tax obligations, executed under a pre-arranged 10b5-1 plan.

Summary

• Jason Adair, Chief Business Officer of Liquidia Corp (LQDA), filed a Form 4 detailing recent equity transactions.
• On June 3, 2025, 12,371 Performance Stock Units (PSUs) vested and converted into common stock on a one-for-one basis.
• These PSUs were part of a grant of 39,588 PSUs on January 11, 2024, with vesting contingent on a time-based schedule and the first commercial sale of YUTREPIA.
• On June 4, 2025, Mr. Adair sold 3,597 shares of common stock at a price of $16.97 per share.
• The sale was conducted to cover taxes associated with the settlement of the vested PSUs.
• The transaction was executed pursuant to a Rule 10b5-1 plan adopted by Mr. Adair on December 15, 2023.
• Following these transactions, Mr. Adair beneficially owns 193,735 shares of Liquidia Corp common stock.
• His holdings include 14,062 unvested Restricted Stock Units (RSUs) from a July 6, 2023 grant, 27,217 unvested RSUs from a January 11, 2024 grant, 61,895 unvested RSUs from a January 11, 2025 grant, and 10,746 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine Form 4 filing detailing the vesting of equity compensation and a subsequent sale of shares to cover tax obligations, which is a common and expected event for executives. The transaction was pre-planned under a 10b5-1 plan, indicating no discretionary selling based on new information.

Positives

• The vesting of 12,371 Performance Stock Units indicates progress towards vesting conditions, including time-based schedules and potentially the commercial sale of YUTREPIA.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned and non-discretionary sale, which is generally viewed positively as it mitigates concerns about opportunistic insider trading.

Negatives

• A sale of 3,597 shares of common stock by a Chief Business Officer, even for tax purposes, reduces the direct equity stake of a key executive in the company.

Risks

• The vesting of PSUs is tied to the commercial sale of YUTREPIA, implying a risk if the product launch or sales performance does not meet expectations, which could affect future equity compensation.

Future Outlook

The document indicates that the vesting of certain PSUs is contingent upon the first commercial sale of YUTREPIA by Liquidia Corp, suggesting a future milestone related to product commercialization.

Management Comments

• The shares were sold to cover taxes associated with the settlement of PSUs that were initially granted to the Reporting Person on January 11, 2024.
• The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. It reflects an executive's equity compensation vesting and subsequent tax-related sales, which are standard practices in the pharmaceutical and biotechnology industries for executive compensation.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for stock sales is a common and recommended practice for corporate insiders across all industries, including biotech, to avoid accusations of trading on material non-public information. This aligns with best practices for executive stock transactions.
• The structure of equity compensation, including PSUs and RSUs with time-based and performance-based vesting, is standard for executive compensation packages in the life sciences sector, similar to companies like United Therapeutics (UTHR) or other pulmonary hypertension drug developers.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even for tax purposes, slightly reduces insider ownership, but the pre-planned nature mitigates negative sentiment. The vesting of PSUs indicates progress towards company milestones.
• Employees: The details of equity grants (PSUs, RSUs, ESPP) highlight the company's compensation structure, which can impact employee retention and motivation.

Next Steps

• Remaining unvested RSUs and PSUs held by the Reporting Person will continue to vest according to their respective schedules, including those contingent on the first commercial sale of YUTREPIA.

Key Dates

Recommendation

Keywords

Liquidia Corp, LQDA, Jason Adair, SEC Form 4, Insider Transaction, Stock Sale, Performance Stock Units, PSUs, Restricted Stock Units, RSUs, Equity Compensation, Rule 10b5-1 Plan, Tax Obligations, YUTREPIA